Discover insights from Cytek Biosciences' Q2 2025 earnings call. Learn about revenue trends, recurring growth, new product launches, and future outlook.

Operating cash flow was just under $28 million, and the company ended the quarter with approximately $50 million in net cash. EPS was $0.59 per share, or $0.63 per share excluding one-time items.

E, pronounced 82 East, was initially founded in 2021 as a Mumbai-based, direct-to-consumer skin care brand offering ...

Go Industries Inc., a well-known provider of truck accessories, law enforcement gear, and custom manufacturing, is excited to ...

Q3 2025 Management View CEO Cheryl P. Beranek highlighted third quarter net sales of $49.9 million, up 2% over the same period in the prior year and "toward the top end of our guidance range, with ...

Q3 2025 Management View CEO Joseph C. Bartolacci reported that the company saw initial benefits from its value creation plan, emphasizing a gain from the divestiture of SGK (now Propelis Group), ...

Key Points Revenue (GAAP) reached $166.7 million for Q2 2025, topping analyst estimates by $4.0 million, with core business sales up 3.9%. Non-GAAP earnings per share were $0.09. Record free cash flow ...

Volo, a leading liquid staking protocol on Sui, today announced the launch of Volo wBTC Vault, a DeFi product designed to ...

Go beyond product displays by creating an atmosphere that reflects the brand’s values, personality and promise.

Steelbird Helmets, has officially announced the launch of its latest product — the Vintage 3.0 Series. This open-face helmet ...

Delta Exchange, India’s leading crypto derivatives platform, today announced the launch of “Trackers” – an innovative new ...